Risk of COVID-19 Infection, Hospitalization, and Mortality in Patients with Psoriasis Treated by Interleukin-17 Inhibitors.

Khalaf KridinYochai SchonmannArie SolomonGiovanni DamianiDana Tzur BitanErez OnnOrly WeinsteinArnon D Cohen

Published in: The Journal of dermatological treatment (2021)

IL-17I treatment does not confer an increased risk of COVID-19 infection or its complications in patients with psoriasis. Our findings support the continuation of IL-17I treatment during the pandemic.

Keyphrases

sars cov
type diabetes
cardiovascular disease
replacement therapy
atopic dermatitis